Dynavax Technologies announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles, a debilitating disease caused by the varicella-zoster virus. The Phase 1/2 trial will be used to support validation of a Patient Reported Outcome measurement tool to differentiate Z-1018 on tolerability and to support potential label claims. Dynavax anticipates reporting top line immunogenicity and safety data in the second half of 2025, including a comparison of CD4+ T-cells one month after the second of two vaccine doses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Dynavax Technologies (NASDAQ:DVAX): A Promising Biopharma Option Despite Recent Challenges
- Biotech Alert: Searches spiking for these stocks today
- Dynavax CRL for four-dose Heplisav-B doesn’t change H.C. Wainwright estimates
- Dynavax provides regulatory update on sBLA for four-dose HEPLISAV-B regimen
- Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates